Bacteremia in human immunodeficiency virus-infected children in Cape Town, South Africa

Pediatr Infect Dis J. 2011 Oct;30(10):904-6. doi: 10.1097/INF.0b013e318220a68b.

Abstract

Bacteremia contributes to morbidity of HIV-infected children. In a randomized controlled trial evaluating trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis, 47 bacteremias were detected. The incidence rate of bacteremia increased in the first 3 months after starting combination antiretroviral therapy (cART), but decreased by 74% once children were established on cART for more than 3 months. Children should be prioritized for early cART.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-HIV Agents / administration & dosage
  • Antibiotic Prophylaxis / methods*
  • Antiretroviral Therapy, Highly Active / methods
  • Bacteremia / epidemiology*
  • Bacteremia / prevention & control*
  • Child
  • Child, Preschool
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • Humans
  • Incidence
  • Infant
  • Male
  • South Africa / epidemiology
  • Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage*

Substances

  • Anti-HIV Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination